GSK and Genmab Announce Topline Results from a Pivotal Head to Head...

GlaxoSmithKline plc and Genmab A/S announced today that the Phase III study of ofatumumab plus chemotherapy versus rituximab plus chemotherapy to treat relapsed or refractory diffuse large B-cell lymphoma did not meet its primary endpoint as there was no statistically significant difference in progression free survival between the treatment arms.

http://ift.tt/1tboXGm